The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS

Current Pharmaceutical Design

Volumn 11, Issue 29, 2005, Pages 3847-3852

  Melroy, Joel ^a   Nair, Vasu ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Abacavir; Combination therapy; Pediatric HIV; Resistance; Reverse transcriptase inhibitor

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBOVIR; DIDANOSINE; DNA; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; BURST FORMING UNIT E; CHILDHOOD DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT INDICATION; VIRUS ISOLATION; VIRUS RESISTANCE; VOMITING; WILD TYPE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CHILD; DIDEOXYNUCLEOSIDES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS;

EID: 27744553956     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580642     Document Type: Review

References (29)

1. Report on the global HIV/AIDS epidemic: December 2002 UNAIDS Joint United Nations Programme on HIV/AIDS.
2. CDC HIV/AIDS Surveillance Report: Cases of HIV infection and AIDS in the United States 2002; 14: 12-13.
3. Sáez-Llorens X, Nelson Jr RP, Emmanuel P, Wiznia A, Mitchell C, Church JA, et al. and the CNAA3006 Study Team. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. Pediatrics 2001; 107(1): e4.
4. De Clerq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002; 11: 13-25.
5. Nair V. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents. Current Pharm Design 2003; 9: 2553-2565,
6. Nair V. Antiviral isonucleosides: discovery, chemistry and chemical biology. In: Chu CK, ed, Recent Advances in Nucleosides: Chemistry and Chemotherapy. Elsevier Science: Amsterdam, Netherlands 2002; pp 149-166.
7. Daluge SM, Good SS, Faletto MB, Miller WH, St. Clair MH, Boone LR, et al. 1592U89, A novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chernother 1997; 41: 1082-1092.
8. Faletto MB, Miller WH, Garvey EP, St. Clair MH, Daluge SM, Good SS. Unique Intracellular Activation of a New Anit-HIV Agent (1592U89) in the Human T-Lymphoblastoid Cell Line CEM-T4. Antimicrob Agents Chemother 1997; 1099-1107.
9. Good SS, Owens BS, Faletto MB, Mahony WB, Domin BA. Disposition in Monkeys and Mice of (1592U89) Succinate, a Potent Inhibitor of HIV. Presentations at the 34th Interscience Conference on Antimicro Agents Chemother October 4-7, 1994; Orlando, Fl.
10. Furman PA, Fyfe JA, St. Clair MH, Qeinhold K, Rideout JL. Freeman GA, et al. Phosphorylation of 3′-azido-3′deozythymidine and selective interaction of the 5′-thriphosphate with human immunodeficiency virus reverse transcriptase. Proc Nail Acad Sci USA 1986; 83: 8333-8337.
11. Huang P, Farquhar D, Plunkett W. Selective action of 3′-azido-3′-deoxythymidine-5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 1990; 265: 11914-11918.
12. St. Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ, et al. 3′-Azido-3-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987; 31: 1972-1977.
13. Nair V, St. Clair M, Reardon JE, Krasny HC, Hazen RJ, Paff MT, et al. Antiviral, metabolic and pharmacokinetic studies on the isomeric dideoxynucleoside, 4(S)-(6-amino-9H-ptuin-9-tetrahydro-2(S)- furanmethanol. Antimicrob Agents Chemother 1995; 39: 1993-1999.
14. Miller WH, Daluge SM, Garvey EP, Hopkins S, Reardon JE, Boyd FL, et al. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J Biol Chem 1992; 267: 21220-21224.
15. Orr DC, Figueiredo HT, Mo CL, Penn CR, Cameron JM. DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2′, 3″-dideoxyguanosine triphosphate. J Biol Chem 1992; 267: 4177-4182.
16. Parker WB, White EL, Shaddiz SC, Ross LJ, Buckheit Jr RW, Germany JM, et al. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases a, b, and c by the 5′-triphosphates of carbovir, 3′azido-3′-deoxythymidine, 2′3′-dideoxyguanosine, and 3′-deoxythymidine. J Biol Chem 1991; 266: 1754-1762.
17. White EL, Parker WB, Macy LJ, Shaddix SC, McCaleb G, Secrist III JA, et al. Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commum 1989; 161: 393-398
18. Tisdale M, Parry NR, Counsens D, St. Clair MH, Boone LR. Anti-HIV Activity of (1592U89). Presentations at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fl; October 4-7, 1994.
19. Pediatric European Network for Treatment of AIDS (PENTA) 2002: Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359: 733-740.
20. Matheron S, Descamps D, Boue F, Livrozet JM, Lafeuillade, A, Aquilina C, et al. The CNA3007 Study Group. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HN-1-infected adults: a randomized trial. Antivir Ther 2003; 8: 163-171.
21. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection: http://www.aidsinfo.nih.gov/guidelines/pediatric/PED_112603.pdf November 26, 2003.
22. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999; 13: 999-1000.
23. Ray AS, Yang Z, Shi J, Hobbs A, Schinazi R, Chu C, et al. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry 2002; 41: 5150-5162.
24. Ray AS, Basavapathruni A, Anderson K. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 2002; 277: 40479-40490.
25. Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, et al. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naïve HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine, or abacavir/zidovudine, with or without nelfinavir (the PENTA5 trial). Antiviral Ther 2002; 7: 293-303.
26. Maggiolo F, Callegaro A, Arici C, Quinzan G, Gregis G, Ripamonti D, et al. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling. Antiviral Ther 2003; 8: 121-126.
27. Liu S, Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Design 2004; 10(15): 1827-43.
28. Thomas SA. Anti-HIV drug distribution to the central nervous system. Curr Pharm Design 2004; 10(12): 1313-24.
29. Tozser J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention, Curr Pharm Design 2003; 9(22):1803-15.